Clarithromycin for improved clinical outcomes in community-acquired pneumonia: A subgroup analysis of the ACCESS trial.
Akinosoglou K, Leventogiannis K, Tasouli E, Kakavoulis N, Niotis G, Doulou S, Skorda L, Iliopoulou K, Papailiou A, Katsaounou P, Rapti V, Chrysos G, Seferlis T, Gerakari S, Dakou K, Papanikolaou IC, Milionis H, Kewitz S, Georgiadou S, Kontopoulou T, Tzavara V, Torres A, Niederman MS, Giamarellos-Bourboulis EJ.
Akinosoglou K, et al.
Int J Antimicrob Agents. 2025 Feb;65(2):107406. doi: 10.1016/j.ijantimicag.2024.107406. Epub 2024 Dec 6.
Int J Antimicrob Agents. 2025.
PMID: 39647798
Free article.
Clinical Trial.
RESULTS: The addition of clarithromycin significantly increased the proportion of patients achieving the primary endpoint across all subgroups and decreased the need for MV in 19 out of the 37 subgroups studied. ...The addition of corticosteroids alone was not as clinicall …
RESULTS: The addition of clarithromycin significantly increased the proportion of patients achieving the primary endpoint across all …